Oncology and Hematology

33-48 of 790

• 

  RestartResume

  Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients

  RestartResume

  Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients

  MinuteCE®

  Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients

  Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD

  0.75 program credits

  • 

    

    Saad Z. Usmani, MD, MBA

  • 

    

    Natalie S. Callander, MD

  0.75 program credits

• 

  RestartResume

  Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients

  RestartResume

  Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients

  MinuteCE®

  Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients

  Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD

  0.75 program credits

  • 

    

    Saad Z. Usmani, MD, MBA

  • 

    

    Natalie S. Callander, MD

  0.75 program credits

• 

  RestartResume

  CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs

  RestartResume

  CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs

  CME/CE

  CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs

  Sagar Lonial, MD, FACP

  1.00 credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 credit

• 

  RestartResume

  3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes

  RestartResume

  3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes

  Project Oncology®

  3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes

  Alexandria May, PharmD, BCPS; Daniel Landi, MD

  • 

    

    Alexandria May, PharmD, BCPS

  • 

    

    Daniel Landi, MD

• 

  RestartResume

  Counseling Patients on Myelofibrosis Treatment Goals and Expectations

  RestartResume

  Counseling Patients on Myelofibrosis Treatment Goals and Expectations

  Project Oncology®

  Counseling Patients on Myelofibrosis Treatment Goals and Expectations

  Shelina Ramnarine, PhD; John Mascarenhas, MD

  • 

    

    Shelina Ramnarine, PhD

  • 

    

    John Mascarenhas, MD

  • 

    

    Marina Kremyanskaya, MD

• 

  RestartResume

  Gastric Cancer Prevention: A Risk-Based Approach

  RestartResume

  Gastric Cancer Prevention: A Risk-Based Approach

  GI Insights

  Gastric Cancer Prevention: A Risk-Based Approach

  Peter Buch, MD, FACG, AGAF, FACP; Chul Hyun, MD, PhD, MPH

  • 

    

    Peter Buch, MD, FACG, AGAF, FACP

  • 

    

    Chul Hyun, MD, PhD, MPH

• 

  RestartResume

  Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer

  RestartResume

  Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer

  Project Oncology®

  Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer

  Steve Jackson, PharmD; Apar Kishor Ganti, MD

  • 

    

    Steve Jackson, PharmD

  • 

    

    Apar Kishor Ganti, MD

  • 

    

    Thomas Marron, MD, PhD

• 

  RestartResume

  Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia

  RestartResume

  Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia

  Project Oncology®

  Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia

  Charles Turck, PharmD, BCPS, BCCCP; Douglas A. Tremblay, MD

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Douglas A. Tremblay, MD

• 

  RestartResume

  Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice

  RestartResume

  Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice

  CME/CE

  Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice

  Amer Zeidan, MBBS; Ghayas Issa, MD

  0.50 credits

  • 

    

    Amer Zeidan, MBBS

  • 

    

    Ghayas Issa, MD

  0.50 credits

• 

  RestartResume

  Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer

  RestartResume

  Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  MinuteCE®

  Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 credit 5 episodes

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 credit 5 episodes

• 

  CME/CE Virtual Event

  Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure

  Multiple dates available

  0.50 credits

• 

  RestartResume

  Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer

  RestartResume

  Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer

  RestartResume

  Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer

  RestartResume

  Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer

  RestartResume

  Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer

  MinuteCE®

  Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• Previous
• 1
• 2
• 3
• 4
• 5
• …
• 49
• 50
• Next